Moreover, a recent in vitro study demonstrated that targeting PD-L1 on SNUC cells using an anti-PD-L1 antibody not only significantly enhanced the immune response against tumor cells but also increased PD-L1 expression in cells that were previously PD-L1-negative, providing the rationale to use immunotherapy alone or in combination in this setting [83]. Here, CD274 is linked to neoplasm.